CL2020000098A1 - Polypeptide molecule with enhanced dual specificity. - Google Patents
Polypeptide molecule with enhanced dual specificity.Info
- Publication number
- CL2020000098A1 CL2020000098A1 CL2020000098A CL2020000098A CL2020000098A1 CL 2020000098 A1 CL2020000098 A1 CL 2020000098A1 CL 2020000098 A CL2020000098 A CL 2020000098A CL 2020000098 A CL2020000098 A CL 2020000098A CL 2020000098 A1 CL2020000098 A1 CL 2020000098A1
- Authority
- CL
- Chile
- Prior art keywords
- cells
- specific
- polypeptide molecule
- dual specificity
- polypeptide chain
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA MOLÉCULA DE POLIPÉPTIDO BIESPECÍFICA QUE COMPRENDE UNA PRIMERA CADENA POLIPEPTÍDICA Y UNA SEGUNDA CADENA POLIPEPTÍDICA QUE PROPORCIONA UNA REGIÓN DE UNIÓN DERIVADA DE UN RECEPTOR DE LINFOCITO T (TCR) QUE ES ESPECÍFICA PARA UN EPÍTOPO PEPTÍDICO ASOCIADO AL COMPLEJO PRINCIPAL DE HISTOCOMPATIBILIDAD (MHC), Y UNA REGIÓN DE UNIÓN DERIVADA DE UN ANTICUERPO CAPAZ DE RECLUTAR CÉLULAS EFECTORAS INMUNITARIAS HUMANAS MEDIANTE LA UNIÓN ESPECÍFICA A UN ANTÍGENO DE SUPERFICIE DE DICHAS CÉLULAS, ASÍ COMO MÉTODOS PARA FABRICAR LA MOLÉCULA DE POLIPÉPTIDO BIESPECÍFICA, Y USOS DE LA MISMA.THE PRESENT INVENTION REFERS TO A BI-SPECIFIC POLYPEPTIDE MOLECULE THAT COMPRISES A FIRST POLYPEPTIDE CHAIN AND A SECOND POLYPEPTIDE CHAIN THAT PROVIDES A BINDING REGION DERIVED FROM A TYPICAL LYMPHOCYTE RECEPTOR (TCR) WHICH IS SPECIFIC TO THE ASCIOPY LYMPHOCYTE PRINCIPLE OF THE PEPIPHEAL PEPIPSE HISTOCOMPATIBILITY (MHC), AND A REGION OF UNION DERIVED FROM AN ANTIBODY CAPABLE OF RECRUITING HUMAN IMMUNE EFFECTIVE CELLS THROUGH THE SPECIFIC BINDING TO A SURFACE ANTIGEN OF SAID CELLS, AS WELL AS MISCELLANEOUS MULTIPLE MULTIPLE CELLS, FOR THE MISCELLANEOUS MULTIPLE POLYESE .
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762532713P | 2017-07-14 | 2017-07-14 | |
DE102017115966.5A DE102017115966A1 (en) | 2017-07-14 | 2017-07-14 | Polypeptide molecule with improved dual specificity |
DE102017119866 | 2017-08-30 | ||
US201862658318P | 2018-04-16 | 2018-04-16 | |
DE102018108995 | 2018-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000098A1 true CL2020000098A1 (en) | 2020-05-29 |
Family
ID=70848164
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000097A CL2020000097A1 (en) | 2017-07-14 | 2020-01-13 | Polypeptide molecule with enhanced dual specificity. |
CL2020000098A CL2020000098A1 (en) | 2017-07-14 | 2020-01-13 | Polypeptide molecule with enhanced dual specificity. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000097A CL2020000097A1 (en) | 2017-07-14 | 2020-01-13 | Polypeptide molecule with enhanced dual specificity. |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2021019626A (en) |
CL (2) | CL2020000097A1 (en) |
HR (1) | HRP20210759T1 (en) |
IL (2) | IL272046A (en) |
PH (2) | PH12020500098A1 (en) |
ZA (1) | ZA202000636B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015012709A (en) * | 2013-03-14 | 2016-05-31 | Macrogenics Inc | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor. |
-
2020
- 2020-01-13 CL CL2020000097A patent/CL2020000097A1/en unknown
- 2020-01-13 CL CL2020000098A patent/CL2020000098A1/en unknown
- 2020-01-14 IL IL272046A patent/IL272046A/en unknown
- 2020-01-14 PH PH12020500098A patent/PH12020500098A1/en unknown
- 2020-01-14 IL IL272045A patent/IL272045A/en unknown
- 2020-01-14 PH PH12020500095A patent/PH12020500095A1/en unknown
- 2020-01-30 ZA ZA2020/00636A patent/ZA202000636B/en unknown
- 2020-10-23 JP JP2020177784A patent/JP2021019626A/en active Pending
-
2021
- 2021-05-12 HR HRP20210759TT patent/HRP20210759T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12020500095A1 (en) | 2020-12-07 |
HRP20210759T1 (en) | 2021-06-11 |
PH12020500098A1 (en) | 2020-12-07 |
CL2020000097A1 (en) | 2020-05-29 |
IL272045A (en) | 2020-03-31 |
IL272046A (en) | 2020-03-31 |
JP2021019626A (en) | 2021-02-18 |
ZA202000636B (en) | 2021-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020001491A2 (en) | Polypeptide molecule with enhanced dual specificity | |
AR110676A1 (en) | TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS | |
CO2018001405A2 (en) | Chimeric antigen receptor based on single domain antibodies | |
CL2018000461A1 (en) | Bispecific antibodies with tetravalence for a co-stimulator fnt receptor. | |
GT201700162A (en) | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123 | |
DOP2019000253A (en) | ANTI-ILT4 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS | |
BR112019007288A2 (en) | bispecific heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing bispecific heterodimeric protein and for treating cancer in a patient | |
CO2017006808A2 (en) | Bcma chimeric antigen receptors | |
CO2017010190A2 (en) | Cd20 therapies, cd22 therapies and combination therapies with a cell that expresses a chimeric antigen (car) receptor of cd19 | |
CO2017000506A2 (en) | Chimeric cll-1 antigen receptor | |
AR104718A1 (en) | RECEIVERS OF ANTI-GD3 SPECIFIC CHEMICAL ANTIGENS FOR IMMUNOTHERAPIES AGAINST CANCER | |
EA201792467A1 (en) | HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | |
BR112018014760A2 (en) | anti-ror1 antibodies, bispecific antibodies to ror1 x cd3 and methods of use | |
AR105433A1 (en) | METHODS TO IMPROVE THE EFFECTIVENESS AND EXPANSION OF IMMUNE CELLS | |
UY35468A (en) | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER | |
UY36289A (en) | MONOCLONAL ANTIBODIES THAT IMMUNE SPECIFICALLY LINK TO CD123 and COMPOSITIONS THAT CONTAIN THEM | |
BR112016022369A2 (en) | cd33-specific chimeric antigen receptors for cancer immunotherapy | |
BR112021016984A2 (en) | dll3-targeted chimeric antigen receptors and binding agents | |
CR20140406A (en) | ANTIBODIES CD47 AND METHODS OF USE OF THE SAME | |
GT201300233A (en) | RECEIVERS OF SIMILAR T-CELLS TO SPECIFIC ANTIBODIES FOR A WT1 PEPTIDE PRESENTED BY HLA-A2 | |
CL2018003515A1 (en) | Anti-gitr antibodies and their uses. | |
BR112022024228A2 (en) | CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS | |
CO2020014343A2 (en) | Cd3-specific antibodies and their uses | |
CO2019003759A2 (en) | Antibodies that bind to the zika virus envelope protein and uses thereof | |
AR112228A1 (en) | POLYPEPTIDE MOLECULE WITH ENHANCED DUAL SPECIFICITY |